Navigation Links
Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
Date:4/25/2008

NEW YORK, April 25 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that the Institutional Review Board (IRB) of the University of Maryland Medical Center (UMMC) has approved UMMC's participation in the Phase III study of the Company's Percutaneous Hepatic Perfusion (PHP) System for the isolated, high dose delivery of the anti-cancer agent melphalan to treat inoperable metastatic melanoma in the liver. The pivotal, Phase III study is being led by the National Cancer Institute (NCI), which previously approved the study's expansion to a multi-center trial.

UMMC has also entered into a clinical research agreement with Delcath enabling the hospital to immediately begin recruiting and treating patients. Richard Alexander, M.D., Professor of Surgery and Chief of Urology at the University of Maryland will serve as Principal Investigator of the study at this new center. Dr. Alexander, a recognized leader in the field of regional cancer therapy, was previously Deputy Director of the NCI's Center for Cancer Research, and Principal Investigator of the Phase I study that was Fast Tracked to this current Phase III study.

"The diagnosis of liver metastases results in a very poor prognosis for the patient," commented Dr. Alexander. "The Delcath System may represent an effective, minimally toxic means of restoring liver health and improving patient outcome. UMMC is committed to remaining at the forefront of cancer research and treatment. We look forward to participating in this NCI-led pivotal study and to understanding how this system may benefit patients."

"Expanding this Phase III study to premier oncology centers such as UMMC remains a top priority for the Company, as it allows the Delcath System to reach more patients desperately in need of new treatment options and expands physician awareness of its potential clinical benefit," said Richard L. Taney, President and CEO of Delcath Systems. "It is especially exciting to be collaborating with Dr. Alexander, who pioneered the use of our PHP system with Melphalan while at the NCI. Throughout 2008, we expect to expand the study to additional clinical sites with world-class clinical oncology programs. Several of these sites are currently in the process of securing the necessary approvals in order to join our clinical trials."

The Phase III Study

The Phase III study is designed to test Delcath's proprietary PHP System for the regional delivery of melphalan to the liver to treat patients with metastatic ocular and cutaneous melanoma who have unresectable tumors in the liver. The Delcath System is designed to deliver significantly higher doses of anti-cancer drugs to a patient's liver while preventing entry of the drugs to the rest of the patient's circulation. This isolation limits toxicities that result from systemic chemotherapy treatments.

Patients in the Phase III trial initially are randomized into one of two treatment arms, including immediate treatment with melphalan via the Delcath System or treatment with best alternative care. The study is designed to evaluate the duration of tumor response in each of the two study arms. Following guidelines established by U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA), when disease progresses in patients enrolled in the best alternative care arm of the trial, they are permitted to "cross over" and receive treatment with the Delcath System.

About University of Maryland Medical Center

The University of Maryland Medical Center (UMMC) is the heart of the University of Maryland Medical System's downtown campus. The hospital provides comprehensive care for the West Baltimore community and tertiary care for Maryland and the surrounding area. In partnership with the University of Maryland School of Medicine, UMMC's vision is to be internationally recognized for world-class clinical programs distinguished by research and education, and strengthened by high-quality clinical care, exceptional customer service and operational excellence.

About Delcath Systems, Inc.

Delcath Systems is a developmental stage company testing its percutaneous perfusion technology for the isolated delivery of high doses of therapeutic and chemotherapeutic agents. The Delcath System is currently being tested with the drug melphalan in Phase III and Phase II clinical trials. The Company's intellectual property portfolio currently consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at http://www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Company Contact:

Delcath Systems, Inc.

Richard Taney

(212) 489-2100

http://www.delcath.com

Media Relations Contact:

The Global Consulting Group

Ivette Almeida

(646) 284-9455

ialmeida@hfgcg.com


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
7. PAREXEL Expands Global Clinical Pharmacology Capabilities
8. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... -- KEY FINDINGS Patient warming and ... loss of blood during surgeries, lowering the risks ... after surgeries, and decreasing risks of SSIs. The ... warming system, surface warming systems, and intravascular warming ... at hospitals thus, lowering the healthcare costs by ...
(Date:12/7/2016)... 7, 2016 Research and Markets has announced ... User - Global Forecast to 2021" report to their offering. ... , , ... by 2021, growing at a CAGR of 7.3% during the forecast period ... prevalence of cancer and rapidly increasing geriatric population across the globe are ...
(Date:12/7/2016)... Dec. 7, 2016 DelveInsight,s, "Janus ... provides in depth insights on the pipeline ... Janus Kinase 3 (JAK3) Inhibitors. The DelveInsight,s ... stages of development including Discovery, Pre-clinical, IND, ... Preregistration. Report covers the product clinical trials ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel of ... of proceeds to two local organizations: North Chicago Animal Control and Friends and Our ... a team of authorized and trained volunteers who support rescued animals held in the ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... Dallas, Texas, is condemning "scam operations" carried out by unethical locksmith companies and ... scam operations to a halt. According to Texas Premier Locksmith, these fraudulent locksmith ...
(Date:12/7/2016)... CA (PRWEB) , ... December 07, 2016 , ... The ... the holidays and winter seasons. One major study analyzing heart attacks among 138,602 ... to August of a given year. We would all agree of course–no time of ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... 2016 BOC Business Brilliance Awards under the Best New Product Launch category. Gensuite’s ... achieved through user experience. , BOC Global Events & Training Group is a ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen ... Program at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years ... three acupuncturists to help patients realize their family building goals. Acupuncture helps ...
Breaking Medicine News(10 mins):